ImmuCell (ICCC) vs Myriad Genetics (MYGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
ImmuCell (ICCC) has outperformed Myriad Genetics (MYGN) over the past year, gaining 50.2% versus a loss of 43.2%. Over five years, ICCC leads with a +4.4% price change compared with -86.5% for MYGN. Myriad Genetics is the larger company by market cap ($397.4 million vs $88.5 million), about 4.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ICCC | MYGN |
|---|---|---|
| Share price | $9.74 | $4.16 |
| Market cap | $88.46M | $397.42M |
| 1-day change | +0.52% | -2.92% |
| YTD return | +57.56% | -30.41% |
| 1-year return | +50.23% | -43.16% |
| 5-year return | +4.42% | -86.52% |
| P/E ratio (TTM) | 139.14 | — |
| EPS (TTM) | $0.07 | $-1.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.10 | $8.59 |
| 52-week low | $4.52 | $2.74 |
| Distance from 52-week high | -19.50% | -51.63% |
| Analyst consensus | — | hold |
| Avg. price target upside | — | -5.90% |
| Average volume | 22.88K | 2.02M |
| Shares outstanding | 9.08M | 95.65M |
| Employees | — | 2,700 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Myriad Genetics is about 4.5 times larger than ImmuCell by market value ($397.42M vs $88.46M).
- ICCC has outperformed MYGN by 93.4 percentage points over the past year.
About Myriad Genetics
MYGN stock →Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 2,700 employees
ICCC vs MYGN FAQ
Which is bigger, ImmuCell or Myriad Genetics?
Myriad Genetics (MYGN) is larger, with a market capitalization of $397.42M compared with $88.46M for ImmuCell (ICCC).
Which stock has performed better over the past year, ICCC or MYGN?
ICCC returned +50.23% over the past 12 months, compared with -43.16% for MYGN (price return, excluding dividends). Past performance does not predict future results.
Are ImmuCell and Myriad Genetics in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.